Laura Mansi

1.9k total citations
30 papers, 373 citations indexed

About

Laura Mansi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Laura Mansi has authored 30 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Laura Mansi's work include Cancer Immunotherapy and Biomarkers (8 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Laura Mansi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Laura Mansi collaborates with scholars based in France, United States and Belgium. Laura Mansi's co-authors include Xavier Pivot, Fernando Bazán, L. Chaigneau, Elsa Curtit, Aurélien Marabelle, Olivier Lambotte, Jean‐Marie Michot, Mihaela Aldea, Florian Scotté and Marie‐Paule Algros and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Laura Mansi

30 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Mansi France 12 228 94 85 80 57 30 373
Yalun Li China 12 164 0.7× 163 1.7× 117 1.4× 89 1.1× 82 1.4× 39 412
Ge Lou China 9 145 0.6× 66 0.7× 161 1.9× 108 1.4× 29 0.5× 23 384
Ana T. Nunes United States 11 275 1.2× 70 0.7× 120 1.4× 52 0.7× 81 1.4× 19 455
H. A. Fritsche United States 7 166 0.7× 83 0.9× 95 1.1× 82 1.0× 61 1.1× 12 384
Meilian Dong China 10 172 0.8× 51 0.5× 121 1.4× 134 1.7× 82 1.4× 17 369
Maria Gonidi Greece 11 146 0.6× 137 1.5× 187 2.2× 76 0.9× 41 0.7× 29 466
Chang Hun Lee South Korea 11 172 0.8× 86 0.9× 92 1.1× 74 0.9× 93 1.6× 29 341
Sotirios Lakis Greece 10 123 0.5× 78 0.8× 74 0.9× 91 1.1× 30 0.5× 21 275
Samuel G.W. Ow Singapore 12 255 1.1× 66 0.7× 99 1.2× 128 1.6× 20 0.4× 50 426

Countries citing papers authored by Laura Mansi

Since Specialization
Citations

This map shows the geographic impact of Laura Mansi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Mansi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Mansi more than expected).

Fields of papers citing papers by Laura Mansi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Mansi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Mansi. The network helps show where Laura Mansi may publish in the future.

Co-authorship network of co-authors of Laura Mansi

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Mansi. A scholar is included among the top collaborators of Laura Mansi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Mansi. Laura Mansi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spehner, Laurie, Fabrice André, Elsa Curtit, et al.. (2025). Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. Breast Cancer Research. 27(1). 19–19. 2 indexed citations
2.
3.
Kfoury, Maria, Domenica Lorusso, Anne Floquet, et al.. (2023). PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. Gynecologic Oncology. 173. 98–105. 18 indexed citations
4.
Bouhaddi, Malika, Pauline Roux, Bruno Degano, et al.. (2022). Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. Frontiers in Cardiovascular Medicine. 9. 1000846–1000846. 16 indexed citations
5.
Vienot, Angélique, Olivier Adotévi, Marion Jacquin, et al.. (2022). A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study. Frontiers in Oncology. 12. 957580–957580. 20 indexed citations
6.
Selmani, Zohair, Fernando Bazán, L. Chaigneau, et al.. (2022). Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry. Scientific Reports. 12(1). 3617–3617. 4 indexed citations
7.
Paquette, Brice, Elsa Kalbacher, Frédéric Mercier, et al.. (2022). Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. Annals of Surgical Oncology. 29(5). 3322–3334. 2 indexed citations
8.
Monnet, Élisabeth, Florence Molinié, Anne‐Valérie Guizard, et al.. (2022). To what extent do age, stage and treatment influence survival after invasive cervical cancer: a French population-based study. Cancer Causes & Control. 33(3). 403–415. 4 indexed citations
9.
Mansi, Laura, Laurie Spehner, Étienne Daguindau, et al.. (2021). Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. European Journal of Cancer. 150. 1–9. 17 indexed citations
10.
Aldea, Mihaela, Laura Mansi, Aurélien Marabelle, et al.. (2020). How to manage patients with corticosteroids in oncology in the era of immunotherapy?. European Journal of Cancer. 141. 239–251. 64 indexed citations
11.
Boullerot, Laura, Caroline Laheurte, Amandine Martin, et al.. (2020). Association of reinvigoration of circulating anti-telomerase CD4 Th1 response in cancer patients with anti-PD-1 response.. Journal of Clinical Oncology. 38(15_suppl). 3044–3044. 1 indexed citations
12.
Boullerot, Laura, Thi Tran, Laura Mansi, et al.. (2018). Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer. 143(11). 3008–3018. 16 indexed citations
13.
Mansi, Laura, Cristian Villanueva, Fabien Calcagno, et al.. (2017). First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report. Oncology Reports. 37(3). 1573–1578. 10 indexed citations
14.
Mansi, Laura, Franck Pagès, & Olivier Adotévi. (2016). Immune Checkpoint Inhibitors. 2. 70–99. 5 indexed citations
15.
Pivot, Xavier, Laura Mansi, L. Chaigneau, et al.. (2015). In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?. The Oncologist. 20(4). 344–350. 19 indexed citations
16.
Curtit, Elsa, Erion Dobi, Laura Mansi, et al.. (2015). Efficacité, tolérance et coût de l’éribuline chez des patientes présentant un cancer du sein métastatique. Bulletin du Cancer. 102(9). 737–748. 2 indexed citations
17.
Curtit, Elsa, Virginie Nerich, Laura Mansi, et al.. (2013). Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis. The Oncologist. 18(6). 667–674. 73 indexed citations
18.
Thiery-Vuillemin, Antoine, Caroline Laheurte, Laura Mansi, et al.. (2013). Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy. 37(1). 51–54. 7 indexed citations
19.
Curtit, Elsa, Laura Mansi, É. Viel, et al.. (2012). KIT et KIT : de la biologie à la clinique. Bulletin du Cancer. 99(2). 191–197. 1 indexed citations
20.
Mansi, Laura, É. Viel, Elsa Curtit, Jacques Médioni, & Christophe Le Tourneau. (2011). Ciblage de la voie de signalisation RAS pour le traitement des cancers. Bulletin du Cancer. 98(9). 1019–1028. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yalun Li Breakdown of academic impact, for papers by Ge Lou Breakdown of academic impact, for papers by Ana T. Nunes Breakdown of academic impact, for papers by H. A. Fritsche Breakdown of academic impact, for papers by Meilian Dong Breakdown of academic impact, for papers by Maria Gonidi Breakdown of academic impact, for papers by Chang Hun Lee Breakdown of academic impact, for papers by Sotirios Lakis Breakdown of academic impact, for papers by Samuel G.W. Ow
Rankless by CCL
2026